Quanterix
QTRX
Market cap $196M

6.06 USD

-0.13

2.10%

At close Jun 13, 4:00 PM EDT

After hours

6.49

+0.43

7.10%

1 day

-2.10%

5 days

10.58%

1 month

30.60%

3 months

-14.77%

6 months

-43.26%

Year to date

-43.68%

1 year

-58.26%

5 years

-76.60%

10 years

-65.31%

About: Quanterix Corp is a life sciences company that focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory and others. Geographically, It operates in North America, EMEA and Asia Pacific.

Employees: 136

Healthcare Medical Devices

0

Funds holding %

of 7,296 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

60% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 35

46% more call options, than puts

Call options by funds: $168K | Put options by funds: $115K

0% more first-time investments, than exits

New positions opened: 37 | Existing positions closed: 37

0.48% less ownership

Funds ownership: 90.88% [Q4 2024] → 90.4% (-0.48%) [Q1 2025]

2% less funds holding

Funds holding: 152 [Q4 2024] → 149 (-3) [Q1 2025]

33% less funds holding in top 10

Funds holding in top 10: 3 [Q4 2024] → 2 (-1) [Q1 2025]

39% less capital invested

Capital invested by funds: $372M [Q4 2024] → $228M (-$144M) [Q1 2025]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$8

32%

upside

Avg. target

$12.67

109%

upside

High target

$18

197%

upside

3 analyst ratings

2 positive

67%

1 neutral

33%

0 negative

0%

Canaccord Genuity Kyle Mikson	98%upside $12	Buy Maintained	13 May 2025
Leerink Partners Puneet Souda	32%upside $8	Market Perform Downgraded	30 Apr 2025
Scotiabank Sung Nam	197%upside $18	Sector Outperform Maintained	25 Mar 2025

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about QTRX published over the past 30 days

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

RINCON, Puerto Rico , June 11, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement condemning the Company's failure thus far to schedule its 2025 Annual Meeting on time. "Quanterix's ongoing failure to schedule its 2025 Annual Meeting until the approaching legal deadline is consistent with the Board's pattern of limiting and disregarding shareholder input.

Kent Lake Condemns Quanterix's Failure to Schedule Its 2025 Annual Meeting as a Tactic to Silence Shareholders

Quanterix to Present at Goldman Sachs Global Healthcare Conference

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that President and Chief Executive Officer Masoud Toloue will present at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami, Florida on Monday, June 9th, at 1:20 p.m. ET. Quanterix will also host one-on-one meetings with institutional investors during the conference. Webcast Information The live webcast prese.

Quanterix to Present at Goldman Sachs Global Healthcare Conference

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

RINCON, Puerto Rico , May 23, 2025 /PRNewswire/ -- Kent Lake PR LLC ("Kent Lake"), a holder of approximately 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ: QTRX), today issued the following statement regarding the Company's Post-Effective Amendment to its S-4 registration statement and Akoya Biosciences' ("Akoya") (NASDAQ: AKYA) disclosure of an unsolicited all-cash offer at $1.40-per-share. "Quanterix's amended merger terms (the "Amended Merger Agreement"), structured to avoid a shareholder vote, already commit the company to pay $20 million in cash alongside 8.4 million newly issued shares in its misguided pursuit of Akoya.

Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

Quanterix Corporation (NASDAQ:QTRX ) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants Joshua Young - Head, IR Masoud Toloue - President and CEO Vandana Sriram - CFO Conference Call Participants Kyle Mikson - Canaccord Sung Ji Nam - Scotiabank Puneet Souda - Leerink Partners Dan Brennan - TD Cowen Operator Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today.

Quanterix Corporation (QTRX) Q1 2025 Earnings Call Transcript

Zacks Investment Research

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Corporation (QTRX) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $0.26 per share a year ago.

Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates

Quanterix Releases Financial Results for the First Quarter of 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, we remain committed to keeping the innovation engine moving forward,” said Masoud Toloue, CEO of Quanterix. "Today, we are excited to announce a major advance: through a new earl.

Quanterix Releases Financial Results for the First Quarter of 2025

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Akoya Biosciences, Inc. (NasdaqGS: AKYA) to Quanterix Corporation (NasdaqGM: QTRX). Under the terms of the proposed transaction, shareholders of Akoya will receive 0.318 shares of Quanterix for each share of Akoya that they own. KSF is seeking to determine whether this consideration and the process that led to.

AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it will host a conference call on Monday, May 12, 2025, at 4:30 p.m. E.T., to discuss its first quarter 2025 financial results. Quanterix will issue a press release regarding its first quarter 2025 financial results prior to the conference call on Monday, May 12, 2025, after the market closes. The press release will be p.

Quanterix To Report First Quarter 2025 Financial Results on May 12, 2025

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

RINCON, Puerto Rico--(BUSINESS WIRE)--Kent Lake PR LLC (“Kent Lake”), a holder of approximately 7.7% of the outstanding common stock of Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), today issued the following statement regarding the Company's announcement of an amended merger agreement (the “Amended Merger Agreement”) related to its proposed merger (the “Merger”) with Akoya Biosciences (“Akoya”) (NASDAQ: AKYA): “Quanterix's decision to press on with the Merger in the face.

Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

BILLERICA, Mass. & MARLBOROUGH, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (NASDAQ: AKYA), The Spatial Biology Company®, today announced an amendment to the terms of their previously announced merger agreement. Under the amended terms, Quanterix will issue approximately 7.76 million shares of its common stock and pay $20 million in cash to Akoya shareholders. Each Akoya s.

Quanterix and Akoya Biosciences Announce Amended Merger Agreement

See News Rankings

Charts implemented using Lightweight Charts™